Thursday 16 October, 2025
Objectives: The aim of this work was to develop a mechanism-based pharmacokinetic-pharmacodynamic (PK/PD) model that describes the longitudinal time-course of…
Read morePoster: Drug/Disease Modelling - Oncology
Lack of pre-clinical target pharmacology: How to predict first-in-human trial dose(s) and inform clinical trial design?
Thursday 16 October, 2025
Introduction: During development of biologic drugs such as monoclonal antibodies (mAb), a major challenge can be posed by the lack…
Read moreA Mixture Tumor Growth Dynamic (TGD) Model to Describe Differential Patterns of Longitudinal Tumor Response of Advanced Melanoma Patients Treated with Ipilimumab
Thursday 16 October, 2025
Introduction: Ipilimumab (IPI) was the first immune-checkpoint inhibitor (ICE) to demonstrate an improvement in overall survival (OS) of advanced melanoma…
Read moreIntegral individualized model of hematopoiesis explains and predicts joint dynamics of thrombocytes, granulocytes and lymphocytes under different chemotherapeutic and adjuvant treatments scenarios
Thursday 16 October, 2025
Objectives: Leukopenia and thrombocytopenia are among the major side-effects of cytotoxic cancer therapies. Maturation of different blood cell lines are interdependent…
Read morePopulation pharmacokinetics and pharmacogenetics analysis of mitotane in adrenocortical carcinoma patients towards individualized dosing
Thursday 16 October, 2025
Introduction: Mitotane, a highly lipophilic compound with an extremely long half-life, is the only agent approved for treatment of adrenocortical…
Read moreQuantitative modelling of exposure-tumor dynamics relationship and development of drug resistance in non-small cell lung cancer patients treated with erlotinib
Thursday 16 October, 2025
Introduction: Erlotinib is an effective targeted treatment of EGFR-mutated non-small-cell lung cancer (NSCLC) [1, 2]. However, the occurrence of acquired…
Read morePopulation pharmacokinetics and toxicity analysis of high-dose methotrexate in patients with central nervous system lymphoma
Thursday 16 October, 2025
Introduction: High-dose methotrexate (HD-MTX) is the backbone of polychemotherapy for central nervous system lymphoma (CNSL)[1]. Although HD-MTX dose is based on…
Read morePopulation pharmacokinetic of tamoxifen and its metabolites in breast cancer patients
Thursday 16 October, 2025
Objectives: Tamoxifen is considered a pro-drug of its active metabolite endoxifen. The major metabolic enzymes involved in endoxifen formation are…
Read moreA kinetic-pharmacodynamic model of palbociclib reveals an influence of body weight on neutropenia onset.
Thursday 16 October, 2025
Objectives: Palbociclib is a cyclin-dependent kinase 4/6 inhibitor labeled for the treatment of estrogenreceptor positive (ER+) and human epidermal growth…
Read morePopulation pharmacokinetics and pharmacodynamics of GSK525762 in patients with solid tumors
Thursday 16 October, 2025
Objectives: To develop a population PK/PD model describing the PK and platelet time profile following oral dosing of a potent…
Read more